Jubilant Pharmova Limited has informed the Exchange about General Updates- Completion of Sale and Transfer of API Business

Core Business DivestedStrategic Transactions View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹1043.90

prior close

₹1041.30

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.6%-1.4% vs market

Pharmaceuticals peers, median of 149sector+0.0%-0.9% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

-0.4

15m

-0.6

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8+0.6-1.4+0.0-0.9

Next day

+0.6+1.4-0.9+0.8-0.3

+1.5+0.8+0.8+0.5+1.1

+2.5+1.0+1.5+0.3+2.2

+4.4+1.2+3.2+0.4+4.0

+6.4+1.4+4.9+0.9+5.5

+7.8+2.1+5.7+1.4+6.4

15d

+3.9+3.1+0.9+1.6+2.4

+7.4+1.7+5.7-0.9+8.2

+11.0+4.2+6.9-1.0+12.1

+4.4-0.3+4.7-4.3+8.7

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Pharmova has completed the sale and transfer of its API (Active Pharmaceutical Ingredients) business, as communicated to the stock exchange. The company has now fully divested this segment, which was a significant part of its pharmaceutical operations. No details on the buyer, deal value, or financial impact have been mentioned in this filing. This marks the conclusion of a previously announced strategic move to exit the API segment.

Likely market impact

Shareholders should expect the company's revenue base to shrink as the API segment is no longer part of the business. The stock may react based on the sale proceeds received and the company's future focus on remaining businesses like radiopharma, contract manufacturing, and drug discovery.